What new advances in treatment—including the availability of amikacin liposome inhalation suspension—and other innovations are positively reshaping our approach to managing MAC lung disease and helping reduce its considerable burden?

What new advances in treatment—including the availability of amikacin liposome inhalation suspension—and other innovations are positively reshaping our approach to managing MAC lung disease and helping reduce its considerable burden?

What new advances in treatment—including the availability of amikacin liposome inhalation suspension—and other innovations are positively reshaping our approach to managing MAC lung disease and helping reduce its considerable burden?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina